(Tiper Stock Exchange) – Svas Biosanaa primary operator in the healthcare sector, active in the production and distribution of medical devices for public and private healthcare facilities, recorded a sales as at 30 June 2023 equal to 55 million, up by 25.6% compared to the same period of the previous year (approximately 43.8 million) with a double digit increase in consolidated revenues.
The increase in the Farmex Business Unit – production and marketing of aids for incontinence and cotton products – which grew by 24.3%, and by Mark Medical Business Unit – marketing of specialist medical devices in Eastern Europe – which increases by 11.3%; Business Units which together account for 63.3% of the Group’s total turnover.
Consolidated turnover as at 30 June 2023 includes revenues of 7 million from the Bormia Group acquired on 23 June 2022.
Umberto Perillo, CEO of Svas Biosanasaid: “We are very satisfied with the growth recorded in the first half. We look with pride at the solidity of the Group and at the favorable prospects for the current and next year. The great work done by the management has made a decisive contribution to the results achieved and will be even more so for future development”.